A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Clinical trial NCT07647328 · RECRUITING

Trial details

NCT number: NCT07647328
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

ER-Positive HER2-Negative Breast Cancer

Start date: 2026-06-15
Primary completion: 2029-02-28
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.